Abstracts tagged "immunology"

Abstract Number: LB18 • ACR Convergence 2025
Transcriptomic Signatures of ANA+ and ANA- B Cells Reveal Shifts from Active Disease to Remission in Systemic Lupus Erythematosus
Rita Pozovskiy¹, Yemil Atisha-Fregoso² and Betty Diamond³, ¹Zucker School of Medicine, New York, New York, ²Feinstein Institutes for Medical Research, New York, New York, ³The Feinstein Institutes for Medical Research, Manhasset, New York
Background/Purpose: In systemic lupus erythematosus (SLE), IgG antibodies that target nuclear antigens (ANA) are pathogenic and part of the diagnostic criteria for SLE. Healthy individuals…
Abstract Number: LB19 • ACR Convergence 2025
Rosnilimab, a Selective and Potent Depleter of Pathogenic T Cells, Demonstrates Efficacy, Safety, and Translational Proof of Mechanism in a Rheumatoid Arthritis Phase 2B Trial
Jonathan Graf¹, Amy Archer², Sergiy Kovalenko³, Katarzyna Kolossa⁴, John Serpa⁵, Tamta Kobakhidze⁶, Daniela Cepoi⁷, Andrea Everding⁸, Costantino Pitzalis⁹, Catherine Aversa², Martin Dahl², May Hafez², Paul Lizzul², Priya Raina², Bruce Randazzo², Yangsu Ren², Khalil Saikali², Cailin Sibley¹⁰, Gerd Burmester¹¹, Jacques-eric GOTTENBERG¹², Iain McInnes¹³, Eduardo Mysler¹⁴, Lee Simon¹⁵, Josef Smolen¹⁶, Jeffrey Sparks¹⁷, Ronald van Vollenhoven¹⁸, Michael Weinblatt¹⁹ and Paul Emery²⁰, ¹UCSF, San Francisco, California, ²AnaptysBio Inc, San Diego, California, ³Arensia Exploratory Medicine, Kyiv, Ukraine, ⁴MICS Centrum Medyczne, Bydgoszcz, Poland, ⁵Allied Biomedical Research Institute, Miami, Florida, ⁶Research Institute of Clinical Medicine Todua Clinic, Tbilisa, Georgia, ⁷Nicolae Testemitanu State University of Medicine & Pharmacy, Chisinau, Moldova, ⁸MVZ Rheumatologie & Autoimmunmedzin Hamburg GmbH, Hamburg, Germany, ⁹QMUL, Bromley Kent, United Kingdom, ¹⁰AnaptysBio Inc, San Diego, ¹¹Charité - Universitétsmedizin Berlin, Berlin, Germany, ¹²Hautepierre Hospital, STRASBOURG, France, ¹³University of Glasgow, Glasgow, United Kingdom, ¹⁴OMI, Buenos Aires, Argentina, ¹⁵SDG LLC, West Newton, Massachusetts, ¹⁶Medical University of Vienna, Vienna, Austria, ¹⁷Brigham and Women's Hospital, Boston, Massachusetts, ¹⁸Amsterdam UMC, Amsterdam, Netherlands, ¹⁹Brigham and Women's Hospital/ Harvard Medical School, Waban, Massachusetts, ²⁰University of Leeds, Leeds, United Kingdom
Background/Purpose: Over 50% of RA patients require multiple b/tsDMARD classes due to inadequate or lost response. Rosnilimab, an investigational monoclonal antibody that selectively targets and…
Abstract Number: 0111 • ACR Convergence 2025
Predicting Response To Adalimumab In Patients With Psoriatic Arthritis Using Epigenetic Chromosome Conformation Signatures
Patricia Riedlova¹, Ewan Hunter², Christine Huppertz³, Maarten de Wit⁴, Stephen R. Pennington⁵, Oliver FitzGerald⁶, Jochen M. Schwenk⁷, Rik Lories⁸, Carl S. Goodyear¹ and Stefan Siebert¹, ¹University of Glasgow, Glasgow, United Kingdom, ²Oxford BioDynamics Plc, Oxford, United Kingdom, ³Novartis Pharma AG, Basel, Switzerland, ⁴Patient Research Partner, Stichting Tools, Amsterdam, Netherlands, ⁵University College Dublin, DUBLIN, Ireland, ⁶UCD, Dublin ⁶, Dublin, Ireland, ⁷KTH Royal Institute of Technology, Solna, Sweden, ⁸KU Leuven, Leuven, Belgium
Background/Purpose: TNF inhibitors (TNFi) have proven efficacy in psoriatic arthritis (PsA) and are commonly prescribed as first line targeted therapy in PsA. However, response to…
Abstract Number: 0888 • ACR Convergence 2025
TargetScan Platform Identifies Targets of CD8+ T cells in Ankylosing Spondylitis and Birdshot Uveitis
Adam S. Weinheimer¹, Olivia Pryor², Catalina Burbano³, Tyler Heath³, Livio Dukaj³, Shoshana M.K. Bloom³, Jackson Lirette³, Rachel Lent³, Prachi Dhanania³, Nicole A. Ladd³, Ryan Kritzer³, Hana Husic³, Shobitha Jillella³, Alexander Cristofaro², Chandan K. Pavuluri³, Jenna LaBelle³, Laurie Barefoot³, Shrikanta Chattopadhyay³, Andrew P. Ferretti³ and Cagan Gurer³, ¹TScan Therapeutics, Boston, MA, ²TScan Therapeutics, Waltham, ³TScan Therapeutics, Waltham, MA
Background/Purpose: Antigen-specific therapies offer a promising approach to selectively modulating autoimmune responses without broad immunosuppression. Strong associations with specific Class I HLA alleles in ankylosing…
Abstract Number: 0963 • ACR Convergence 2025
Increased expression of M2 pro-fibrotic markers in circulating monocytes and cultured monocyte-derived macrophages from systemic sclerosis patients with progressive interstitial lung disease (ILD)
Vanessa Smith¹, Stefano Soldano², Rosanna Campitiello³, Emanuele Gotelli³, Paola Montagna⁴, Tamara Vojinovic⁴, Sabrina Paolino², Carmen Pizzorni², Alberto Sulli² and Maurizio Cutolo⁵, ¹Ghent University Hospital, Gent, Belgium, ²University of Genoa, Genova, Italy, ³University of Genoa, Genoa, Liguria, Italy, ⁴University of Genoa, Genova, ⁵University of Genova, Genova, Italy
Background/Purpose: In the complex pathogenesis of systemic sclerosis (SSc), macrophages are mainly involved in mechanism of progressive tissue fibrosis of skin and internal organs, particularly…
Abstract Number: 1140 • ACR Convergence 2025
PGG Suppresses MSU Crystal–Triggered Inflammation and Arachidonic Acid Production in PBMCs
Sadiq Umar¹, Poorna Chandra Rao Yalagala², Sugasini Dhavamani² and Sriram Ravindran², ¹University of Illinois at Chicago, Chicago, IL, ²University of Illinois, Chicago, IL
Background/Purpose: Gout is the most prevalent inflammatory arthritis globally, with rising incidence in both developed and developing regions. It is driven by monosodium urate (MSU)…
Abstract Number: 1715 • ACR Convergence 2025
Spondyloarthritis and Psoriatic Arthritis Patients Under Immunosuppressive Conventional and Biologic DMARDs: Favorable Disease Safety and Attenuated Immunogenicity Following Recombinant Herpes Zoster Vaccination
Carla Saad¹, Eduardo Borba², Fernanda Chaer³, Ana C Medeiros-Ribeiro¹, Sandra G Pasoto¹, Nadia Emi Aikawa⁴, Luisa Correia⁵, Percival Sampaio-Barros⁶, Julio Moraes⁷, Murillo Dorio¹, Claudia Goldenstein-Schainberg¹, Clovis Artur Silva⁸ and Eloisa Bonfa², ¹Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, ²Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, ³Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Santos, Brazil, ⁴Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, São Paulo, Brazil, ⁵Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, ⁶Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, Brazil, ⁷Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Jundiai, Brazil, ⁸University of São Paulo, São Paulo, São Paulo, Brazil
Background/Purpose: Psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) patients are at increased risk for herpes zoster(HZ) due to impaired cell-mediated immunity associated with the underlying…
Abstract Number: 2019 • ACR Convergence 2025
Incidence of Coronavirus Disease 2019 in Participants with IgG4-Related Disease Treated with Inebilizumab in the MITIGATE Study
Arezou Khosroshahi¹, Emma Culver², Wen Zhang³, Kazuichi Okazaki⁴, Yoshiya Tanaka⁵, Matthias Lohr⁶, nicolas schleinitz⁷, Xinxin Dong⁸, Sue Cheng⁸, Daniel Cimbora⁸ and John Stone⁹, ¹Emory University, Atlanta, GA, ²John Radcliffe Hospital; University of Oxford, Oxford, United Kingdom, ³Peking Union Medical College Hospital, Dong Cheng Qu, China (People's Republic), ⁴Kansai Medical University Kori Hospital, Osaka, Japan, ⁵University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁶Karolinska Institutet, Stockholm, Sweden, ⁷Aix Marseille university, AP-HM, Marseille, France, ⁸Amgen, Thousand Oaks, CA, ⁹Massachusetts General Hospital , Harvard Medical School, Concord, MA
Background/Purpose: The potential of B-cell-depleting therapies to diminish humoral responses is recognized, but whether this leads to an increased risk of Coronavirus Disease 2019 (COVID-19)…
Abstract Number: 2439 • ACR Convergence 2025
Belimumab Versus Mycophenolate Mofetil in Lupus Nephritis: A Real-World Comparative Analysis
Ahmad Alomari¹, Nikita Shah², Miguel Rodriguez³ and Diala Alawneh⁴, ¹UCF- North Florida hospital, Gainesville, FL, ²UCF/HCA Florida North Florida Hospital, Gainesville, FL, ³SIMED Rheumatology, Gainesville, FL, ⁴University of Florida, Gainesville, FL
Background/Purpose: Lupus nephritis (LN) is a serious complication of systemic lupus erythematosus (SLE), often leading to chronic kidney disease (CKD) and end-stage renal disease (ESRD).…
Abstract Number: 0206 • ACR Convergence 2025
Prospective Controlled Study of Humoral Response to Recombinant Zoster Vaccine in Cyclophosphamide-Treated Autoimmune Rheumatic Disease Patients: No Additional Impairment Compared to Other Immunosuppressive Therapies
Nadia Emi Aikawa¹, Julia Medeiros², Sandra G Pasoto³, Ana C Medeiros-Ribeiro³, Luciana Parente Costa Seguro⁴, Ana Paula Luppino-Assad⁵, Emily Figueiredo Neves Yuki⁶, Lissiane Guedes⁷, Clovis Artur Silva⁸ and Eloisa Bonfa⁴, ¹Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, São Paulo, Brazil, ²Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, ³Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, ⁴Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, ⁵Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SAO PAULO, Brazil, ⁶Faculdade de Medicina da USP, São Paulo, São Paulo, Brazil, ⁷Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, ⁸University of São Paulo, São Paulo, São Paulo, Brazil
Background/Purpose: Recombinant zoster vaccine (RZV), represents a major advancement in the prevention of herpes zoster in autoimmune rheumatic diseases (ARD) patients. However, RVZ efficacy depends…
Abstract Number: 0890 • ACR Convergence 2025
Granzyme K+ CD8 T cells colocalize with myeloid cells and activate them through several pathways
Julia Nicole Zeid¹, Kaitlyn Arce², Nanxi Guo¹, Kartik Bhamidipati³, Kevin Wei⁴, Larry Moreland⁵, Fan Zhang⁶ and Anna Helena Jonsson², ¹University of Colorado School of Medicine, Aurora, ²University of Colorado School of Medicine, Aurora, CO, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ⁵University of Colorado, Denver, CO, ⁶The University of Colorado, Aurora, CO
Background/Purpose: Granzyme K (GZMK)-expressing CD8 T cells have recently been detected in tissues from an increasing number of autoimmune conditions, but their role in disease…
Abstract Number: 0979 • ACR Convergence 2025
IL-23 upregulates IFN-γ secretion in Th17.1, but not in Th17 or classical Th1 cells
Bennie van Heeswijk¹, Wida Razawy², Anne-Marie Mus-Otten³, Patrick Asmawidjaja², Pieter Leenen² and Erik Lubberts⁴, ¹Erasmus MC, University Medical Center Rotterdam, Hoofddorp, Netherlands, ²Erasmus University Medical Center, Rotterdam, the Netherlands, Rotterdam, Netherlands, ³Erasmus medical center, Rotterdam, Netherlands, ⁴Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands
Background/Purpose: Interleukin-23 (IL-23) is a key cytokine in the pathogenesis of psoriatic diseases, as demonstrated by the clinical success of IL-23-targeted therapies. Monocytes are a…
Abstract Number: 1141 • ACR Convergence 2025
Modulation of Inflammatory Responses by Dental Pulp Stem Cell Extracellular Vesicles in Monosodium Urate-Stimulated Macrophages
Sadiq Umar¹, Kasey Leung² and Sriram Ravindran², ¹University of Illinois at Chicago, Chicago, IL, ²University of Illinois, Chicago, IL
Background/Purpose: Gout is the most prevalent form of inflammatory arthritis, with rising global incidence. It results from the deposition of monosodium urate (MSU) crystals in…
Abstract Number: 1723 • ACR Convergence 2025
Impaired Maintenance of X-Chromosome Inactivation in B Cells, But Not T Cells, Exacerbates Interferon-Driven Systemic Autoimmunity
Nikhil Jiwrajka¹, Claudia Lovell¹, Zowie Searcy¹, Katherine Forsyth¹, Emma Welter¹, Natalie Toothacre², Nuriban Valero-Pacheco¹, Katherine Premo¹ and Montserrat Anguera¹, ¹University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia
Background/Purpose: Many systemic autoimmune diseases associated with chronic type 1 interferon (IFN) signaling, including SLE, SjD, and SSc, preferentially afflict females. The biological basis of…
Abstract Number: 2020 • ACR Convergence 2025
Inebilizumab Efficacy and Safety in Patients with Common, Urgent, and Fibrotic Organ Manifestations of IgG4-RD: Subgroup Analyses from the MITIGATE Trial
Arezou Khosroshahi¹, Emma Culver², Wen Zhang³, Kazuichi Okazaki⁴, Yoshiya Tanaka⁵, Matthias Lohr⁶, nicolas schleinitz⁷, Xinxin Dong⁸, Sue Cheng⁸, Daniel Cimbora⁸ and John Stone⁹, ¹Emory University, Atlanta, GA, ²John Radcliffe Hospital; University of Oxford, Oxford, United Kingdom, ³Peking Union Medical College Hospital, Dong Cheng Qu, China (People's Republic), ⁴Kansai Medical University Kori Hospital, Osaka, Japan, ⁵University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁶Karolinska Institutet, Stockholm, Sweden, ⁷Aix Marseille university, AP-HM, Marseille, France, ⁸Amgen, Thousand Oaks, CA, ⁹Massachusetts General Hospital , Harvard Medical School, Concord, MA
Background/Purpose: IgG4-related disease (IgG4-RD) is a progressive, systemic, fibroinflammatory disease characterized by unpredictable and recurring flares, leading to organ damage and decreased quality of life.…

1
2
3
…
33
Next Page »

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].